Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
113,145,145
-
Share change
-
+11,003,984
-
Total reported value
-
$475,143,333
-
Put/Call ratio
-
70%
-
Price per share
-
$4.20
-
Number of holders
-
131
-
Value change
-
+$35,158,478
-
Number of buys
-
71
-
Number of sells
-
59
Institutional Holders of CTI BIOPHARMA CORP - COM (CTIC) as of Q1 2023
As of 31 Mar 2023,
CTI BIOPHARMA CORP - COM (CTIC) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
113,145,145 shares.
The largest 10 holders included
STATE STREET CORP, Rubric Capital Management LP, BVF INC/IL, BlackRock Inc., Stonepine Capital Management, LLC, MARSHALL WACE, LLP, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, Bleichroeder LP, and NEA Management Company, LLC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.